Anonymous
|
Deloitte Recap LLC Announces the Launch of the
Recap IQ Series by Deloitte
In July 2008, Recombinant Capital, Inc. was purchased by Deloitte LLP and is now known as Deloitte Recap LLC (Recap). Recap offers biopharmaceutical business intelligence subscription tools and consulting services tailored toward business development, corporate strategy, financial, legal, academic, and R&D professionals.
In July 2009, Recap launched DEAL builder and VALUATION analyzer, the first two premium database modules in the Recap IQ Series by Deloitte. The subscription database products within the new IQ Series provide analytical tools to help Life Sciences companies leverage comprehensive biopharma alliance data, deal values, and drug development histories to support the development of alliance and clinical development strategies.
DEAL builder and VALUATION analyzer are biopharma business intelligence tools for managing alliance formation, the lifecycle of the alliance, and deal valuations. These modules offer unique insights into biopharma alliances via access to unredacted, unpublished agreements secured through Freedom of Information Act requests of the U.S. Securities and Exchange Commission.
In September 2009, Recap launched the third product, DEVELOPMENT optimizer, within the Recap IQ Series.
DEVELOPMENT optimizer is a groundbreaking business intelligence tool that is changing how clinical development decisions are made. Designed with the same meticulous, data-rich approach that is the hallmark of the Recap brand, DEVELOPMENT optimizer offers new ways to look at attrition, development and regulatory performance, and termination efficiency. This new product offers unique analytics backed by detailed drug development histories to provide competitive intelligence for business and clinical development.
| Yours sincerely, | Mark G. Edwards
Principal
Deloitte Recap LLC |
|
| To commemorate the launch of Recap Basic, we are delighted to unveil a breakthrough tool for Effective Royalty Rate (EFR) analysis. This tool, which we call the EFR Grapher, allows you to perform real-time searches of over a thousand biopharma alliances to see the post-launch payments negotiated for deals matching your criteria and stage of clinical development. |
|
|
|
 |
Steady As She Goes
Biotech and specialty pharma firms raised nearly $14 billion in the first half of 2010 – and if the pace continues for the rest of the year, it could be a record-breaker.
|
|
|
|
|
 |
Recap IQ by Deloitte
Intelligent toolkits for biopharmaceutical business intelligence
Tools for alliance and clinical development strategies |
|
 |
Explore RecapRx,
in our database of the 20 Compounds That Defined Biotech. Complete coverage of
marketed indications for the Top 20 biotech drugs: clinical timelines, individual trial
details, supporting regulatory documents & abstracts.
|
|
 |
RecapIP,
a new way to explore & understand biotech intellectual property. Patents & patent applications, linked to their commercial agreements,
reveal a world of 'partnered IP' that has been inaccessible until
now.
|
|
 |
 | Alliance Structuring & Deal Valuation |
| Expert Testimony & Litigation Support |
| Alliance Portfolio Evaluation |
| Investment Due Diligence |
We
can help you.
|
|
 |
Inside Biotech
Why Recap.com works for you
Explanations on our Databases can be found here.
|
|
 |
Allicense
2010
Redefining the Threshold of Innovation
Conference Concluded
Thank you
Speakers & Attendees
|
|
|